—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Intellia Therapeutics Inc (NTLA) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for NTLA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.95 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How NTLA has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.95 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Intellia Therapeutics Inc moved 0.95% on average · correlation 0.09 · higher than 85% of US names
  • Beta, last 3 months 2.64 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.05% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −1.38% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against NTLA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Intellia Therapeutics Inc

NTLA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Intellia Therapeutics is a clinical-stage genome-editing company that develops therapies using CRISPR/Cas9 technology to edit genes inside and outside the body. Its lead programmes target transthyretin amyloidosis and hereditary angioedema, alongside work in immuno-oncology and autoimmune disease. It also licenses its editing platform to partners including Regeneron, AvenCell, Kyverna, ONK Therapeutics, SparingVision and ReCode for their own cell and gene therapy programmes. It is based in Cambridge, Massachusetts.
Where it sits in the stack
Intellia carries no seat in our index and sits outside the AI build-out stack the diary tracks; it belongs to the biotechnology sleeve of our wider universe, grouped by its genome-editing platform rather than by any hardware or compute layer.
Who it is priced against
Closelooknet has not set a peer group for this name; the wider market groups it with other clinical-stage CRISPR developers such as CRISPR Therapeutics and Editas Medicine.
Why Closelooknet tracks it
Intellia holds no index seat and carries no Closelooknet score yet; there are no editions or quotes on record for this name in the diary.
What the diary watches
Whether any of its in vivo or ex vivo programmes advance through clinical trials, and whether the partnered platform deals produce new licensing or collaboration terms worth tracking.

Intellia Therapeutics Inc (NTLA) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Wedbush, 2026-09-09

The Street on this name

Analyst actions and the latest print for NTLA from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Wedbush — target 13 from 12 Target raised to $13 from $12 (+2.8% to spot) 2026-09-09

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Intellia Therapeutics Inc (NTLA)?

Intellia Therapeutics Inc trades as NTLA on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is NTLA in a Closelooknet index?

Not currently — Intellia Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does NTLA trade against its moving averages?

Mixed moving-average stack: Trades -1.6% vs the 50-day and -8.1% vs the 200-day average, 58.4% below the 52-week high and +47.8% off the 52-week low; a death cross printed 11 sessions ago. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Intellia Therapeutics Inc trade when bond yields rise?

Over the past year Intellia Therapeutics Inc had a beta of 0.95 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 85% of US names. On the 10 sessions in which long bonds fell most it moved −1.05% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Intellia Therapeutics Inc do?

Intellia Therapeutics is a clinical-stage genome-editing company that develops therapies using CRISPR/Cas9 technology to edit genes inside and outside the body. Its lead programmes target transthyretin amyloidosis and hereditary angioedema, alongside work in immuno-oncology and autoimmune disease. It also licenses its editing platform to partners including Regeneron, AvenCell, Kyverna, ONK Therapeutics, SparingVision and ReCode for their own cell and gene therapy programmes. Closelooknet has not set a peer group for this name; the wider market groups it with other clinical-stage CRISPR developers such as CRISPR Therapeutics and Editas Medicine.

Where does Intellia Therapeutics Inc sit in the AI build-out?

Intellia carries no seat in our index and sits outside the AI build-out stack the diary tracks; it belongs to the biotechnology sleeve of our wider universe, grouped by its genome-editing platform rather than by any hardware or compute layer. Intellia holds no index seat and carries no Closelooknet score yet; there are no editions or quotes on record for this name in the diary.

What has Wall Street done on Intellia Therapeutics Inc recently?

The most recent analyst action on Intellia Therapeutics Inc on the Closelooknet wire is a price target by Wedbush on 2026-09-09 (target 13 from 12). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for NTLA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.